Cumberland Pharmaceuticals (NASDAQ:CPIX) & Scilex (NASDAQ:SCLX) Head-To-Head Survey

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares Cumberland Pharmaceuticals and Scilex”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52 million	2.23	-$2.84 million	$4.49	1.48
Scilex	$30.25 million	0.44	-$358.73 million	($49.70)	-0.03

Cumberland Pharmaceuticals has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 4.5% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cumberland Pharmaceuticals and Scilex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	274.38%	-31.40%	-9.38%
Scilex	-1,414.57%	N/A	-147.00%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cumberland Pharmaceuticals and Scilex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1	0	0	0	1.00
Scilex	1	0	0	0	1.00

Risk and Volatility

Cumberland Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Summary

Cumberland Pharmaceuticals beats Scilex on 8 of the 11 factors compared between the two stocks.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company headquartered in Nashville, Tennessee. The company develops, acquires and commercializes prescription medicines, with a focus on products that address unmet needs in critical care, gastroenterology, pain management and other specialty areas. Its portfolio has included Caldolor (ibuprofen injection), Acetadote (acetylcysteine injection), Kristalose (lactulose for oral solution), Vaprisol (conivaptan hydrochloride injection) and Omeclamox-Pak, a treatment for certain Helicobacter pylori infections.

About Scilex

Scilex Holding Company (NASDAQ:SCLX) is a pharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. The company’s portfolio is intended to address conditions that may otherwise require opioid-based therapies, with an emphasis on prescription medicines and locally or systemically delivered treatments. Scilex’s commercial products include ZTlido, a prescription lidocaine topical system approved for the treatment of pain associated with postherpetic neuralgia; ELYXYB, an oral solution of celecoxib indicated for the acute treatment of migraine with or without aura in adults; and Gloperba, an oral liquid formulation of colchicine used to treat and prevent gout flares.